Personalised therapy for multiple sclerosis
At the present time, no neuroregenerative or remyelinating therapies are available for clinical use and so the core of multiple sclerosis management lies in preventing clinical relapses and relapse-related disability accrual.
Despite the rapid development of pharmacotherapy, prevention of disability in patients with multiple sclerosis has been suboptimal. The most effective of the available immunotherapies mitigate the short-term risk of disability progression by 30-42%. This imperfect result is mainly attributed to the large inter-individual variability in the multiple sclerosis phenotype and treatment response. From the patients’ perspective, any time spent on disease modifying therapies with suboptimal individual effect translates into ongoing loss of capacity. While an enormous effort is being invested into developing new, more potent therapies, it is of paramount importance that use of the currently available therapies is optimised.
This project uses MSBase, a large international MS cohort study, to evaluate demographic, clinical, paraclinical, radiological and biological predictors of future response to multiple sclerosis therapies and to develop a predictive algorithm applicable in clinical practice.
- Dr Tomas Kalincik, project leader
- MSBase collaborators (117 MS centre in 35 countries), teams at Karolinska Institute (Stockholm) and University Hospital Vall d'Hebron (Spain)
- NHMRC project grant 108353, Treating progressive MS.
- University of Melbourne Research Fellowship.
This research project is available to PhD students to join as part of their thesis.
Please contact the Research Group Leader to discuss your options.
- Jokubaitis V, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D, et al., on behalf of the MSBase Study Group (in press) Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol
- Uher T, Vaneckova M, Sobisek L. . . Kalincik T and Horakova D (in press) Combining clinical and MRI predictors enhances prediction of 12-year disability in multiple sclerosis. Mult Scler
- Uher T, Horakova D, Kalincik T, Bergsland N, Tyblova M, Ramasamy D, et al. (in press) Early MRI predictors of clinical progression over 48 months in patients with clinically isolated syndrome treated with intramuscular interferon β1a. Eur J Neurol
- Jokubaitis VG, Spelman T, Kalincik T, Izquierdo G, Grand’Maison F, Duquette P et al., on behalf of the MSBase Study Group (2015) Predictors of disability worsening in clinically isolated syndrome. Ann Clin Transl Neurol 2(5):479-91
- Horakova D, Kalincik T, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E (2012) Early predictors of non-response to interferon in multiple sclerosis. Acta Neurol Scand 126(6):390-7